Fewer than 8 percent of U.S. medical schools include indoor environmental health as a required component of their curriculum, according to a survey of accredited medical programs conducted by the Association of American Medical Colleges and published in February 2026. The finding helps explain why mold-related illness remains dramatically underdiagnosed despite a growing body of evidence documenting its health effects.
The gap is not merely educational. Even physicians who recognize mold illness face a fundamental treatment constraint: there is no pharmaceutical intervention that addresses the underlying cause. Antifungals treat invasive fungal infections, not the systemic inflammation and immune dysregulation caused by mycotoxin exposure. The only effective treatment is removal from the contaminated environment and professional remediation.
This dynamic creates a structural disincentive. Physicians trained in pharmaceutical-based medicine have limited tools to offer mold-illness patients, and the diagnosis does not generate a prescription. Some physicians, aware of this limitation, avoid the diagnosis entirely to prevent patient frustration.
Functional medicine practitioners and environmental health specialists have largely filled the gap, but their services are rarely covered by insurance, creating an equity problem: wealthier patients can access diagnosis and guidance, while lower-income patients in the most mold-affected housing stock cannot.
Advocacy groups are pushing for mandatory indoor environmental health training in medical education and for insurance coverage of environmental health consultations. The MOLD Act, currently before Congress, includes provisions for CDC-funded physician education programs.
